These compounds target key melanoma-associated pathways (see Figure 2), including p53, Bcl-2, caspases 3 and 9, MAPK, MEK/ERK, PI3K/Akt, and the cyclin-dependent kinase (Cdk) pathways. This evidence concerns the gene BCL2 and melanoma.